Alexei Agapitov, MD
Cardiovascular Disease · Madison, WINPI 1841201514
Payments from drug & device makers
Across 27 payments — averaging $72.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Daiichi Sankyo Inc.$80
- Amgen$70
- Novo Nordisk$25
- Cvrx, Inc.$22
- Scpharmaceuticals Inc.$16
What the payments were for
- Travel & lodging$1,40771%
- Food & beverage$56429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 17 | $1,759 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Amgen | 4 | $70 |
| Novo Nordisk | 1 | $25 |
| Cvrx, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,335
How this compares
$1,971 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 358 | $485,156 |
| JardianceEmpagliflozin | 131 | $184,045 |
| EntrestoSacubitril/Valsartan | 139 | $164,012 |
| XareltoRivaroxaban | 57 | $83,899 |
| FarxigaDapagliflozin Propanediol | 60 | $66,197 |
| Repatha SureclickEvolocumab | 65 | $51,984 |
| VascepaIcosapent Ethyl | 49 | $32,137 |
| Metoprolol Succinate | 513 | $6,736 |
| Atorvastatin Calcium | 546 | $5,395 |
| Icosapent Ethyl | 18 | $3,673 |
| Rosuvastatin Calcium | 310 | $3,653 |
| Spironolactone | 406 | $2,781 |
| Nebivolol Hcl | 19 | $2,228 |
| Losartan Potassium | 249 | $2,205 |
| Carvedilol | 236 | $2,088 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Madison
- Paul HinderakerMadison$463K
- David PhamMadison$425K
- Farhan RazaMadison$359K
- Peter MasonMadison$274K
- David SloskyMadison$247K
- Meisam MoghbelliMadison$173K
- Peter RahkoMadison$122K
- Peter MarogilMadison$64K
- Matthew TattersallMadison$56K
- Abraham JacobMadison$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.